CA3041648A1 - Cognitive platform configured as a biomarker or other type of marker - Google Patents
Cognitive platform configured as a biomarker or other type of marker Download PDFInfo
- Publication number
- CA3041648A1 CA3041648A1 CA3041648A CA3041648A CA3041648A1 CA 3041648 A1 CA3041648 A1 CA 3041648A1 CA 3041648 A CA3041648 A CA 3041648A CA 3041648 A CA3041648 A CA 3041648A CA 3041648 A1 CA3041648 A1 CA 3041648A1
- Authority
- CA
- Canada
- Prior art keywords
- individual
- interference
- response
- primary
- task
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001149 cognitive effect Effects 0.000 title claims abstract description 369
- 239000000090 biomarker Substances 0.000 title description 20
- 239000003550 marker Substances 0.000 title description 16
- 230000004044 response Effects 0.000 claims abstract description 496
- 238000000034 method Methods 0.000 claims abstract description 159
- 230000000626 neurodegenerative effect Effects 0.000 claims abstract description 148
- 230000003930 cognitive ability Effects 0.000 claims abstract description 61
- 238000012545 processing Methods 0.000 claims description 256
- 238000004458 analytical method Methods 0.000 claims description 173
- 238000005259 measurement Methods 0.000 claims description 120
- 239000003814 drug Substances 0.000 claims description 119
- 229940079593 drug Drugs 0.000 claims description 112
- 238000012549 training Methods 0.000 claims description 100
- 239000008177 pharmaceutical agent Substances 0.000 claims description 86
- 230000008859 change Effects 0.000 claims description 58
- 230000015654 memory Effects 0.000 claims description 57
- 238000011282 treatment Methods 0.000 claims description 48
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 42
- 230000033001 locomotion Effects 0.000 claims description 41
- 238000004448 titration Methods 0.000 claims description 34
- 238000013542 behavioral therapy Methods 0.000 claims description 30
- 238000009223 counseling Methods 0.000 claims description 30
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 24
- 229960001344 methylphenidate Drugs 0.000 claims description 24
- 238000009877 rendering Methods 0.000 claims description 20
- 230000003287 optical effect Effects 0.000 claims description 18
- 238000011269 treatment regimen Methods 0.000 claims description 18
- 208000024827 Alzheimer disease Diseases 0.000 claims description 17
- 208000023105 Huntington disease Diseases 0.000 claims description 16
- 206010012289 Dementia Diseases 0.000 claims description 15
- 208000018737 Parkinson disease Diseases 0.000 claims description 15
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 14
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 14
- 238000003745 diagnosis Methods 0.000 claims description 12
- 238000007477 logistic regression Methods 0.000 claims description 11
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 9
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 9
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 9
- 229950008995 aducanumab Drugs 0.000 claims description 9
- 238000013528 artificial neural network Methods 0.000 claims description 9
- 230000003190 augmentative effect Effects 0.000 claims description 9
- 229950001954 crenezumab Drugs 0.000 claims description 9
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 9
- 229960003135 donepezil hydrochloride Drugs 0.000 claims description 9
- 229960004323 rivastigmine tartrate Drugs 0.000 claims description 9
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 9
- 229960002646 scopolamine Drugs 0.000 claims description 9
- 239000010454 slate Substances 0.000 claims description 9
- 229950007874 solanezumab Drugs 0.000 claims description 9
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 claims description 9
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 8
- 102000015833 Cystatin Human genes 0.000 claims description 8
- 102000016252 Huntingtin Human genes 0.000 claims description 8
- 108050004784 Huntingtin Proteins 0.000 claims description 8
- LDDHMLJTFXJGPI-LFPUEVJFSA-N [(3s,5r)-3,5-dimethyl-1-adamantyl]azanium;chloride Chemical compound Cl.C1C(C2)C[C@@]3(C)C[C@]1(C)CC2(N)C3 LDDHMLJTFXJGPI-LFPUEVJFSA-N 0.000 claims description 8
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 8
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 8
- 108050004038 cystatin Proteins 0.000 claims description 8
- 238000012417 linear regression Methods 0.000 claims description 8
- 102000013498 tau Proteins Human genes 0.000 claims description 8
- 108010026424 tau Proteins Proteins 0.000 claims description 8
- 238000000513 principal component analysis Methods 0.000 claims description 7
- 238000007637 random forest analysis Methods 0.000 claims description 7
- 238000012706 support-vector machine Methods 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 230000003044 adaptive effect Effects 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims 1
- 230000003993 interaction Effects 0.000 description 146
- 230000000670 limiting effect Effects 0.000 description 139
- 230000000694 effects Effects 0.000 description 59
- 230000003935 attention Effects 0.000 description 56
- 238000012360 testing method Methods 0.000 description 53
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 44
- 101150037123 APOE gene Proteins 0.000 description 34
- 238000012544 monitoring process Methods 0.000 description 29
- 230000002452 interceptive effect Effects 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 210000004556 brain Anatomy 0.000 description 23
- 230000000007 visual effect Effects 0.000 description 21
- 238000004891 communication Methods 0.000 description 19
- 230000008685 targeting Effects 0.000 description 19
- 238000003860 storage Methods 0.000 description 18
- 230000019771 cognition Effects 0.000 description 16
- 230000009471 action Effects 0.000 description 15
- 230000002996 emotional effect Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000001054 cortical effect Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 238000004590 computer program Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 230000000704 physical effect Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 11
- 238000010801 machine learning Methods 0.000 description 10
- 238000002600 positron emission tomography Methods 0.000 description 10
- 230000035484 reaction time Effects 0.000 description 10
- 230000003542 behavioural effect Effects 0.000 description 9
- 230000005714 functional activity Effects 0.000 description 9
- 230000003936 working memory Effects 0.000 description 9
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000008921 facial expression Effects 0.000 description 8
- 238000007726 management method Methods 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000008449 language Effects 0.000 description 6
- 230000007659 motor function Effects 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000004962 physiological condition Effects 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
- 238000004497 NIR spectroscopy Methods 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 238000002582 magnetoencephalography Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 231100000430 skin reaction Toxicity 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000036992 cognitive tasks Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 230000010332 selective attention Effects 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 210000000857 visual cortex Anatomy 0.000 description 4
- 206010013710 Drug interaction Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007787 long-term memory Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000003557 neuropsychological effect Effects 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 210000002442 prefrontal cortex Anatomy 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000010344 pupil dilation Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000006403 short-term memory Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 2
- 210000004727 amygdala Anatomy 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000008309 brain mechanism Effects 0.000 description 2
- -1 but not limited to Chemical compound 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000007370 cognitive improvement Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000000537 electroencephalography Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000001073 episodic memory Effects 0.000 description 2
- 230000004424 eye movement Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000011337 individualized treatment Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000010295 mobile communication Methods 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 230000007996 neuronal plasticity Effects 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 230000001179 pupillary effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000011952 auditory verbal learning test Methods 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000004633 cognitive health Effects 0.000 description 1
- 230000006998 cognitive state Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000007595 memory recall Effects 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 230000008555 neuronal activation Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008430 psychophysiology Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009155 sensory pathway Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0024—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system for multiple sensor units attached to the patient, e.g. using a body or personal area network
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0531—Measuring skin impedance
- A61B5/0533—Measuring galvanic skin response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/162—Testing reaction times
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/167—Personality evaluation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/168—Evaluating attention deficit, hyperactivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/242—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents
- A61B5/245—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
- A61B5/246—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals using evoked responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/377—Electroencephalography [EEG] using evoked responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
- A61B5/6868—Brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient; User input means
- A61B5/7475—User input or interface means, e.g. keyboard, pointing device, joystick
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B5/00—Electrically-operated educational appliances
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B5/00—Electrically-operated educational appliances
- G09B5/06—Electrically-operated educational appliances with both visual and audible presentation of the material to be studied
- G09B5/065—Combinations of audio and video presentations, e.g. videotapes, videodiscs, television systems
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B7/00—Electrically-operated teaching apparatus or devices working with questions and answers
- G09B7/02—Electrically-operated teaching apparatus or devices working with questions and answers of the type wherein the student is expected to construct an answer to the question which is presented or wherein the machine gives an answer to the question presented by a student
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/242—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents
- A61B5/245—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6887—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient mounted on external non-worn devices, e.g. non-medical devices
- A61B5/6898—Portable consumer electronic devices, e.g. music players, telephones, tablet computers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Developmental Disabilities (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Psychology (AREA)
- Data Mining & Analysis (AREA)
- Hospice & Palliative Care (AREA)
- Educational Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Artificial Intelligence (AREA)
- Physiology (AREA)
- Databases & Information Systems (AREA)
- Social Psychology (AREA)
- Theoretical Computer Science (AREA)
- Business, Economics & Management (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Educational Administration (AREA)
- Signal Processing (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Dermatology (AREA)
- Fuzzy Systems (AREA)
- Evolutionary Computation (AREA)
- Mathematical Physics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412215P | 2016-10-24 | 2016-10-24 | |
| US62/412,215 | 2016-10-24 | ||
| PCT/US2017/058103 WO2018081134A1 (en) | 2016-10-24 | 2017-10-24 | Cognitive platform configured as a biomarker or other type of marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3041648A1 true CA3041648A1 (en) | 2018-05-03 |
Family
ID=62023978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041648A Pending CA3041648A1 (en) | 2016-10-24 | 2017-10-24 | Cognitive platform configured as a biomarker or other type of marker |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11690560B2 (enExample) |
| EP (1) | EP3531915B1 (enExample) |
| JP (1) | JP7125390B2 (enExample) |
| AU (1) | AU2017347975B2 (enExample) |
| CA (1) | CA3041648A1 (enExample) |
| ES (1) | ES3002383T3 (enExample) |
| WO (1) | WO2018081134A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7771320B2 (en) | 2006-09-07 | 2010-08-10 | Nike, Inc. | Athletic performance sensing and/or tracking systems and methods |
| US12399564B2 (en) | 2012-08-31 | 2025-08-26 | Blue Goji Llc | Treatment of neurological functioning and conditions using computer-assisted dual-task methodology |
| US11914776B2 (en) | 2012-08-31 | 2024-02-27 | Blue Goji Llc | System and method for evaluation, detection, conditioning, and treatment of neurological functioning and conditions |
| US11304657B2 (en) | 2016-08-26 | 2022-04-19 | Akili Interactive Labs, Inc. | Cognitive platform coupled with a physiological component |
| US12138069B2 (en) | 2016-12-13 | 2024-11-12 | Akili Interactive Labs, Inc. | Platform for identification of biomarkers using navigation tasks and treatments using navigation tasks |
| WO2019246032A1 (en) * | 2018-06-19 | 2019-12-26 | Neurocern, Inc. | System and method for providing a neurological assessment of a subject |
| WO2019245865A1 (en) * | 2018-06-19 | 2019-12-26 | Tornier, Inc. | Mixed reality indication of points at which 3d bone and implant models collide |
| CN109044374B (zh) * | 2018-07-19 | 2021-05-14 | 杭州心景科技有限公司 | 整合视听连续执行测试方法、装置及系统 |
| EP3621276A1 (en) * | 2018-09-05 | 2020-03-11 | Altoida Ltd. | Apparatus, method and program for determining a cognitive state of a user of a mobile device |
| US11258629B2 (en) * | 2018-09-18 | 2022-02-22 | Hyena Lic. | Controlling system for electric bicycle and method thereof |
| US11500922B2 (en) * | 2018-09-19 | 2022-11-15 | International Business Machines Corporation | Method for sensory orchestration |
| EP3627444B1 (en) * | 2018-09-20 | 2024-06-26 | L'oreal | Method and system for determining a characteristic of a keratinous surface and method and system for treating said keratinous surface |
| US12026636B2 (en) | 2018-10-15 | 2024-07-02 | Akili Interactive Labs, Inc. | Cognitive platform for deriving effort metric for optimizing cognitive treatment |
| CA3115994A1 (en) * | 2018-10-15 | 2020-04-23 | Akili Interactive Labs, Inc. | Cognitive platform for deriving effort metric for optimizing cognitive treatment |
| AU2019384870B2 (en) * | 2018-11-23 | 2025-07-10 | The Wellness App Ip Inc. | Micro-coherence network strength and deep behavior modification optimization application |
| US12347548B2 (en) * | 2019-03-13 | 2025-07-01 | Bright Cloud International Corporation | Medication enhancement systems and methods for cognitive benefit |
| EP3946029A4 (en) * | 2019-03-28 | 2022-12-21 | Zoll Medical Corporation | Systems and methods for providing drug prescription information with monitored cardiac information |
| US10811138B1 (en) * | 2020-03-11 | 2020-10-20 | Memorial Sloan Kettering Cancer Center | Parameter selection model using image analysis |
| US11960383B2 (en) * | 2020-04-01 | 2024-04-16 | Akili Interactive Labs, Inc. | Systems and methods for software design control and quality assurance |
| US20220061726A1 (en) * | 2020-08-28 | 2022-03-03 | Sentio Solutions, Inc. | Method for characterizing, detecting, and monitoring adhd |
| JP7359112B2 (ja) * | 2020-09-11 | 2023-10-11 | トヨタ自動車株式会社 | 注意能力検査装置および注意能力検査方法 |
| US20220101981A1 (en) * | 2020-09-28 | 2022-03-31 | xSensa Labs | Method and system for neuromodulation |
| JP7705964B2 (ja) | 2021-02-22 | 2025-07-10 | ニューロード ピーティーワイ リミテッド | 神経学的状態の症状をモニタリングするための機器、システム及び方法 |
| WO2022209499A1 (ja) * | 2021-03-29 | 2022-10-06 | ソニーグループ株式会社 | 情動情報を表示する情報処理システム |
| US11944436B2 (en) * | 2021-04-10 | 2024-04-02 | Koa Health Digital Solutions S. L. U. | Determining a stress level of a smartphone user based on the user's touch interactions and motion sensor data |
| CA3222403A1 (en) * | 2021-06-17 | 2022-12-22 | Altoida, Inc. | Method and system for obtaining measurement of cognitive performance |
| US12224055B2 (en) | 2021-06-17 | 2025-02-11 | Akili Interactive Labs, Inc. | System and method for adaptive configuration of computerized cognitive training programs |
| WO2023276977A1 (ja) * | 2021-06-28 | 2023-01-05 | 富士フイルム株式会社 | 医療支援装置、医療支援装置の作動方法、医療支援装置の作動プログラム |
| US20230055265A1 (en) * | 2021-08-10 | 2023-02-23 | Sarah McEwen | Audio-based interactive simultaneous exercise and cognitive control training for improving cognitive networks subserving neuropsychiatric and neurocognitive conditions |
| US12148102B2 (en) * | 2021-08-25 | 2024-11-19 | Sony Interactive Entertainment Inc. | Dynamic augmentation of stimuli based on profile of user |
| KR20230044977A (ko) * | 2021-09-27 | 2023-04-04 | (주)이모티브 | 학습 기반 사용자 맞춤형 인지 모델을 이용하여, 인지검사 태스크를 대체 수행하는 인지모델 기반의 인지 상태 평가 리포팅 제공 방법 및 그 장치 |
| JP7514020B2 (ja) | 2021-09-27 | 2024-07-10 | ロゴスサイエンス株式会社 | 治療システム |
| JP7452516B2 (ja) * | 2021-10-28 | 2024-03-19 | トヨタ自動車株式会社 | 注意能力検査装置、および、車両 |
| US20230197217A1 (en) * | 2021-12-16 | 2023-06-22 | Matrixcare, Inc. | Automated notifications of changes to medical records |
| CN117731312A (zh) | 2022-09-13 | 2024-03-22 | 上海联影医疗科技股份有限公司 | 一种医学图像的扫描方法和系统 |
| WO2024159294A1 (ru) * | 2023-01-31 | 2024-08-08 | Общество С Ограниченной Ответственностью "Тотал Геймз" | Система дистанционной оценки психологического состояния |
| CN116458887B (zh) * | 2023-05-29 | 2025-04-08 | 中科(安徽)G60智慧健康创新研究院 | 一种儿童多动症监测与训练方法、装置及设备 |
| US12362059B2 (en) | 2023-07-17 | 2025-07-15 | NXTech Inc | Neurostimulation with gamified self-control training exercises |
| WO2025019425A1 (en) * | 2023-07-17 | 2025-01-23 | NXTech Inc | Substance usage management with gamified self-control training exercises |
| CN117608411B (zh) * | 2024-01-23 | 2024-03-22 | 北京北测数字技术有限公司 | 基于脑机接口的信号传输处理方法及系统 |
| ES2971764A1 (es) * | 2024-04-10 | 2024-06-06 | Univ Valencia Politecnica | Metodo y equipo de analisis de la experiencia de usuario |
| WO2025216707A1 (en) * | 2024-04-11 | 2025-10-16 | Nanyang Technological University | Module and method for generating a cognitive score based on digital biomarkers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1562464A4 (en) * | 2002-11-05 | 2008-09-17 | Univ Rochester | METHOD FOR EVALUATING NAVIGATIONAL PERFORMANCE |
| JP4431731B2 (ja) | 2003-11-07 | 2010-03-17 | 新治 村上 | 認知機能評価システム |
| US20090298025A1 (en) | 2007-05-09 | 2009-12-03 | Oregon Health & Science University | Object recognition testing tools and techniques for measuring cognitive ability and cognitive impairment |
| JP2011083403A (ja) | 2009-10-15 | 2011-04-28 | Hokkaido Univ | 認知機能評価システム |
| US20120108909A1 (en) | 2010-11-03 | 2012-05-03 | HeadRehab, LLC | Assessment and Rehabilitation of Cognitive and Motor Functions Using Virtual Reality |
| CA2720892A1 (en) | 2010-11-12 | 2012-05-12 | The Regents Of The University Of California | Enhancing cognition in the presence of distraction and/or interruption |
| US9943250B2 (en) | 2011-10-09 | 2018-04-17 | The Medical Research, Infrastructure amd Health Services Fund of the Tel Aviv Medical Center | Freezing of gait (FOG), detection, prediction and/or treatment |
| WO2013056082A1 (en) * | 2011-10-12 | 2013-04-18 | The Johns Hopkins University | Methods for evaluating regional cardiac function and dyssynchrony from a dynamic imaging modality using endocardial motion |
| ES2853550T3 (es) | 2011-11-16 | 2021-09-16 | Bohbot Veronique Deborah | Entorno de realidad virtual tridimensional generado por ordenador para mejorar la memoria |
| WO2015066037A1 (en) | 2013-10-28 | 2015-05-07 | Brown University | Virtual reality methods and systems |
| CA2949431C (en) | 2014-05-21 | 2023-09-26 | Akili Interactive Labs, Inc. | Processor-implemented systems and methods for enhancing cognitive abilities by personalizing cognitive training regimens |
| US20160078780A1 (en) | 2014-09-15 | 2016-03-17 | The Arizona Board Of Regents For And On Behalf Of The University Of Arizona | Method and System for Aerobic and Cognitive Training |
| US20160125748A1 (en) * | 2014-11-04 | 2016-05-05 | John Wesson Ashford | Memory test for Alzheimer's disease |
| US10449359B2 (en) | 2015-01-24 | 2019-10-22 | The Trustees Of The University Of Pennsylvania | Method and apparatus for improving cognitive performance |
| WO2016145372A1 (en) | 2015-03-12 | 2016-09-15 | Akili Interactive Labs, Inc. | Processor implemented systems and methods for measuring congnitive abilities |
| CN107636468A (zh) | 2015-04-02 | 2018-01-26 | Crc心理健康有限公司 | 用于预测认知退化的风险的方法 |
| US10410140B1 (en) * | 2016-08-17 | 2019-09-10 | Amazon Technologies, Inc. | Categorical to numeric conversion of features for machine learning models |
| US10401369B2 (en) | 2016-11-08 | 2019-09-03 | Magqu Co. Ltd. | Method for discriminating Parkinson's disease dementia from Parkinson's disease with normal cognition |
-
2017
- 2017-10-24 JP JP2019521747A patent/JP7125390B2/ja active Active
- 2017-10-24 CA CA3041648A patent/CA3041648A1/en active Pending
- 2017-10-24 US US16/344,074 patent/US11690560B2/en active Active
- 2017-10-24 WO PCT/US2017/058103 patent/WO2018081134A1/en not_active Ceased
- 2017-10-24 AU AU2017347975A patent/AU2017347975B2/en active Active
- 2017-10-24 EP EP17865415.8A patent/EP3531915B1/en active Active
- 2017-10-24 ES ES17865415T patent/ES3002383T3/es active Active
-
2023
- 2023-07-01 US US18/217,566 patent/US12220242B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240000370A1 (en) | 2024-01-04 |
| WO2018081134A1 (en) | 2018-05-03 |
| AU2017347975A1 (en) | 2019-05-16 |
| US12220242B2 (en) | 2025-02-11 |
| US11690560B2 (en) | 2023-07-04 |
| JP2020500360A (ja) | 2020-01-09 |
| JP7125390B2 (ja) | 2022-08-24 |
| EP3531915A4 (en) | 2020-04-22 |
| ES3002383T3 (en) | 2025-03-06 |
| US20200060603A1 (en) | 2020-02-27 |
| AU2017347975B2 (en) | 2023-08-03 |
| EP3531915A1 (en) | 2019-09-04 |
| EP3531915B1 (en) | 2024-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12220242B2 (en) | Cognitive platform configured as a biomarker or other type of marker | |
| US12016700B2 (en) | Cognitive platform coupled with a physiological component | |
| US12236005B2 (en) | Cognitive platform including computerized elements | |
| WO2018132483A1 (en) | Cognitive platform configured for determining the presence or likelihood of onset of a neuropsychological deficit or disorder | |
| US20190159716A1 (en) | Cognitive platform including computerized evocative elements | |
| WO2019161050A1 (en) | Cognitive platform including computerized elements coupled with a therapy for mood disorder | |
| US20200380882A1 (en) | Cognitive platform including computerized evocative elements in modes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220531 |
|
| EEER | Examination request |
Effective date: 20220531 |
|
| EEER | Examination request |
Effective date: 20220531 |
|
| EEER | Examination request |
Effective date: 20220531 |
|
| EEER | Examination request |
Effective date: 20220531 |
|
| EEER | Examination request |
Effective date: 20220531 |